Document is current
Any future updates will be listed below
-
Authors
Mohyuddin, Ghulam Rehman https://orcid.org/0000-0001-6464-783X
Mian, Hira https://orcid.org/0000-0003-1584-1067
Gayowsky, Anastasia
Seow, Hsien
Chakraborty, Rajshekhar https://orcid.org/0000-0001-7336-3003
Pond, Gregory R.
Al Hadidi, Samer https://orcid.org/0000-0003-4297-8042
Visram, Alissa https://orcid.org/0000-0002-7201-4642
- License Information
-
More Information
Article History
Received: 17 July 2024
Revised: 4 October 2024
Accepted: 8 October 2024
First Online: 16 October 2024
Competing interests
: HM: Advisory Board/Consultancy- Janssen, BMS, Pfizer, Takeda, Sanofi, Abbvie; Research Funding: Janssen, Pfizer. AV: Advisory board: Janssen, Forus therapeutics, Sanofi, Pfizer; Research funding: Janssen. GM: Payments for writing from MashupMD. Research funding to institution: Janssen. SA: Advisory/Consultancy: Janssen, Pfizer, Sanofi. RC: Advisory/Consultancy: Janssen, Sanofi, Adaptive.
